Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Amneal Pharmaceuticals (AMRX) Form 144 discloses a proposed sale of 33,436 Common Class A shares through Charles Schwab (3000 Schwab Way, Westlake, TX) with an aggregate market value of $304,100.00. The filing reports 314,079,309 shares outstanding and lists the approximate sale date as 08/12/2025 on NASDAQ. The shares were acquired as restricted stock awards from the issuer on 03/03/2025 (14,779 shares) and 03/04/2025 (18,657 shares) and were paid via Equity Compensation. The filer reports Nothing to Report for securities sold in the past three months and includes the standard representation that no material nonpublic information is known.
Amneal Pharmaceuticals (AMRX) Form 144 reports a proposed sale of 22,000 Class A shares through Merrill Lynch with an approximate sale date of 08/12/2025 and an aggregate market value of $198,000. The filing shows the shares were acquired on 03/03/2025 as equity compensation from Amneal Pharmaceuticals and that payment was made on the same date.
The filing lists 18,067,134 shares outstanding and indicates there were no securities sold by the person in the past three months. The filer also represents that they have no undisclosed material adverse information about the issuer.
Form 144 filing for Amneal Pharmaceuticals (AMRX) reports a proposed insider sale of 50,000 shares of common stock with an aggregate market value of $453,000. The filing lists 314,079,309 shares outstanding, and the approximate date of sale is 08/12/2025 on Nasdaq. The shares were originally acquired on 07/05/2018 as equity compensation.
The filing also discloses a recent sale of 49,140 shares on 05/16/2025 generating $370,541, and includes the standard insider representation that the seller is not aware of any undisclosed material adverse information. The notice documents compliance with Rule 144 procedures but does not provide additional operational or financial data.
Chirag K. Patel reports beneficial ownership of 22,180,421 shares of Amneal Pharmaceuticals Class A common stock, representing 7.1% of the class based on 314,079,309 shares outstanding. Of that total, Mr. Patel directly owns 857,980 shares and holds options for 24,977 and 28,044 shares; trusts he controls hold 21,269,420 shares. The filing states no transactions in the past 60 days and shows sole voting and dispositive power over the reported shares.
The filing also discloses an Omnibus Amendment to the Margin Loan Agreement and Pledge and Security Agreement dated August 6, 2025, which increases the collateral pledged to 19,000,000 shares and extends the loan maturity to April 29, 2028. The amended Pledge and Security Agreement is filed as an exhibit.
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K announcing a two-part debt refinancing initiative. Its operating subsidiary is marketing $1.8 billion of new seven-year term loan B debt and has launched a private offering of $750 million senior secured notes due 2032. Net proceeds are earmarked to (i) refinance the company’s existing term B loans in full, (ii) repay a portion of borrowings under the ABL facility, and (iii) cover related fees and expenses.
The notes will be issued under Rule 144A/Reg S and will not be registered with the SEC. Completion, size and terms of both transactions remain subject to market conditions; the notes offering is not contingent on closing of the new term loan facility. No financial results or forward guidance were provided.
Key takeaways for investors:
- Potentially extends weighted-average debt maturity to 2032.
- Transaction could restructure up to $2.55 billion of the capital stack.
- Execution risk exists because neither transaction is assured.
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K announcing a two-part debt refinancing initiative. Its operating subsidiary is marketing $1.8 billion of new seven-year term loan B debt and has launched a private offering of $750 million senior secured notes due 2032. Net proceeds are earmarked to (i) refinance the company’s existing term B loans in full, (ii) repay a portion of borrowings under the ABL facility, and (iii) cover related fees and expenses.
The notes will be issued under Rule 144A/Reg S and will not be registered with the SEC. Completion, size and terms of both transactions remain subject to market conditions; the notes offering is not contingent on closing of the new term loan facility. No financial results or forward guidance were provided.
Key takeaways for investors:
- Potentially extends weighted-average debt maturity to 2032.
- Transaction could restructure up to $2.55 billion of the capital stack.
- Execution risk exists because neither transaction is assured.
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) filed an 8-K dated 21-Jul-2025 disclosing two principal items:
- Item 2.02 – Preliminary Q2 2025 results: The company issued a press release (Ex. 99.1) with unaudited second-quarter figures. Numerical details are not included in the filing; the release is incorporated by reference but treated as “furnished,” not “filed,” under the Exchange Act.
- Item 5.02 – Board change: Ownership of Class A shares held by Amneal Group investors fell below a majority threshold, reducing their Board designee rights from six to five under the Stockholders Agreement. Consequently, Amneal Group designee Emily Peterson Alva resigned from the Board and Audit Committee effective 16-Jul-2025. The company states the resignation involved no disagreement with management, the Board, or company policies.
No other material transactions, financial statements, or guidance updates are provided in this report. The filing contains customary Regulation FD and exhibit listings.
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) filed an 8-K dated 21-Jul-2025 disclosing two principal items:
- Item 2.02 – Preliminary Q2 2025 results: The company issued a press release (Ex. 99.1) with unaudited second-quarter figures. Numerical details are not included in the filing; the release is incorporated by reference but treated as “furnished,” not “filed,” under the Exchange Act.
- Item 5.02 – Board change: Ownership of Class A shares held by Amneal Group investors fell below a majority threshold, reducing their Board designee rights from six to five under the Stockholders Agreement. Consequently, Amneal Group designee Emily Peterson Alva resigned from the Board and Audit Committee effective 16-Jul-2025. The company states the resignation involved no disagreement with management, the Board, or company policies.
No other material transactions, financial statements, or guidance updates are provided in this report. The filing contains customary Regulation FD and exhibit listings.